# Trends of Microorganisms and Antibiotic Resistance Isolated from Patients with Bacterial Keratitis from a Tertiary Hospital in Southeastern Korea: A 26-Year Retrospective Medical Record Review

**Authors:** Chan-Ho Cho, Jong Ho Lee, Sang-Bumm Lee

PMC · DOI: 10.3390/antibiotics15020207 · Antibiotics · 2026-02-13

## TL;DR

This study analyzed 26 years of bacterial keratitis cases in Korea and found rising trends in certain antibiotic-resistant bacteria, suggesting potential future treatment challenges.

## Contribution

The study provides a long-term retrospective analysis of bacterial keratitis trends and antibiotic resistance patterns in a Korean hospital setting.

## Key findings

- Acinetobacter spp. increased significantly from 1.3% to 10.6% over the study period.
- Vancomycin-resistant Enterococci increased from 0% to 26.1%, though not statistically significant.
- Resistance to aminoglycosides decreased significantly among Gram-negative bacteria.

## Abstract

Background. The aim of this study is to analyze changing trends in isolated organisms and antibiotic resistance of bacterial keratitis (BK) over 26 years. Methods. A retrospective medical record review included 542 strains isolated from 462 BK patients between 1998 and 2023. We analyzed routinely generated in vitro antibiotic susceptibility testing results recorded in the laboratory information system and did not perform additional susceptibility testing for research purposes. The entire period was divided into two (first half: 1998–2010, 297 isolates from 255 patients; second half: 2011–2023, 245 isolates from 207 patients) and compared. Results. During the entire period, Staphylococcus spp. (32.3%) and Pseudomonas spp. (18.1%) were common isolates, and a significant increase in Acinetobacter spp. (1.3% vs. 10.6%, p < 0.001) was observed. Among Gram-positive bacteria, methicillin resistance rates remained stable between the two periods (52.6% vs. 46.7%, p = 0.525), and an increase in vancomycin-resistant Enterococci (VRE, 0% vs. 26.1%, p = 0.074) was found. Among Gram-negative bacteria (GNB), ciprofloxacin (7.5% vs. 14.4%, p = 0.108) and imipenem (2.9% vs. 6.5%, p = 0.255) resistance increased slightly, resistance to ceftazidime (8.3% vs. 8.8%, p > 0.999) was maintained, and resistance to aminoglycosides (17.8% vs. 7.2%, p = 0.010) decreased. Conclusions. Our study suggests that conventional topical fortified antibiotic eye drops (tobramycin, ceftazidime) can still be considered as an empirical treatment option for BK. However, our findings revealed a long-term trend of increasing Acinetobacter spp. and VRE, as well as a slight trend of increasing resistance to ciprofloxacin and imipenem in GNB, which may present future challenges in BK treatment.

## Linked entities

- **Chemicals:** tobramycin (PubChem CID 36294), ceftazidime (PubChem CID 5481173), ciprofloxacin (PubChem CID 2764), imipenem (PubChem CID 104838), vancomycin (PubChem CID 14969)
- **Species:** Pseudomonas sp. #P (taxon 299395), Acinetobacter sp. P (taxon 596119)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), CRE (MESH:D060467), MSSE (MESH:C536150), ocular surface disease (MESH:D010534), MDR (MESH:D018088), Antibiotic Resistance (MESH:D004761), ophthalmic infections (MESH:C535922), GPB infections (MESH:D016908), branch trauma (MESH:D014947), hemolysis (MESH:D006461), ulcers (MESH:D014456), ESBL infection (MESH:D007239), MRPA (MESH:D011552), BK (MESH:D007634), nosocomial infections (MESH:D003428), acanthamoeba keratitis (MESH:D015823), infectious keratitis (MESH:D003141), ESBL (MESH:C538111), MRSA (MESH:D013203), corneal trauma (MESH:D065306), Corneal Ulcers (MESH:D003320), fungal (MESH:D009181), GNB (MESH:D016905), coagulase-negative staphylococci (MESH:D064726), bacterial infections (MESH:D001424)
- **Chemicals:** tigecycline (MESH:D000078304), beta-lactam antibiotic (MESH:D008997), sulbactam-durlobactam (MESH:C000714947), agar (MESH:D000362), ciprofloxacin (MESH:D002939), cefiderocol (MESH:C000612166), piperacillin (MESH:D010878), aminoglycoside (MESH:D000617), cefoxitin (MESH:D002440), teicoplanin (MESH:D017334), methicillin (MESH:D008712), gentamicin (MESH:D005839), moxifloxacin (MESH:D000077266), proparacaine hydrochloride (MESH:C005717), tobramycin (MESH:D014031), levofloxacin (MESH:D064704), meropenem (MESH:D000077731), cefepime (MESH:D000077723), ceftazidime (MESH:D002442), Carbapenems (MESH:D015780), Vancomycin (MESH:D014640), synercid (MESH:C062940), ticarcillin (MESH:D013982), ertapenem (MESH:D000077727), water (MESH:D014867), linezolid (MESH:D000069349), rifampicin (MESH:D012293), amikacin (MESH:D000583), fluoroquinolone (MESH:D024841), cephalosporins (MESH:D002511), nitrofurantoin (MESH:D009582), ceftazidime-avibactam (MESH:C000595613), Aztreonam (MESH:D001398), cefotaxime (MESH:D002439), BLBLI (-), meropenem-vaborbactam (MESH:C000654127), beta-lactam (MESH:D047090), potassium hydroxide (MESH:C029943), TMP/SMX (MESH:D015662), cefazolin (MESH:D002437), glycopeptide (MESH:D006020), minocycline (MESH:D008911), CO2 (MESH:D002245), oxacillin (MESH:D010068), thioglycolate (MESH:D013864), Steroids (MESH:D013256), ampicillin (MESH:D000667), Imipenem (MESH:D015378)
- **Species:** Haemophilus (genus) [taxon 724], Pseudomonas aeruginosa (species) [taxon 287], Escherichia coli (E. coli, species) [taxon 562], Acanthamoeba (genus) [taxon 5754], Enterobacterales (order) [taxon 91347], Klebsiella (genus) [taxon 570], Serratia (genus) [taxon 613], Ovis aries (domestic sheep, species) [taxon 9940], Enterococcus casseliflavus (species) [taxon 37734], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Enterococcus gallinarum (species) [taxon 1353], Streptococcus (genus) [taxon 1301], Glomus sp. PB (species) [taxon 1166547], Achromobacter (genus) [taxon 222], Enterococcus faecium (species) [taxon 1352], Leclercia (genus) [taxon 83654], Acinetobacter baumannii (species) [taxon 470]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937251/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937251/full.md

## References

66 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937251/full.md

---
Source: https://tomesphere.com/paper/PMC12937251